Boehringer Ingelheim and Carelon Research have conducted a validation study of the Klinrisk model, a …
The World’s First “Recombinant Anthrax Vaccine”: GC Biopharma applies for MFDS Approval
GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of “GC1109”, an …
Vesica Health Appoints Distinguished Urologic Oncologist Dr. William T. Lowrance to Chief Medical Officer
VESICA HEALTH, INC., a multi-omics, liquid biopsy company transforming the management of hematuria patients and …
Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics, a leading CDMO that enables its partners’ success in biologics, and Hope Medicine Inc. …
Pulmonary Fibrosis Foundation and Pulmonary Hypertension Association Provide Guidance on Pulmonary Hypertension Related to Interstitial Lung Disease
The Pulmonary Fibrosis Foundation (PFF) and Pulmonary Hypertension Association have developed a position statement that addresses gaps in the …
Positive results from first-in-human completely leadless CRT in the US, published in The Journal of the American College of Cardiology
EBR Systems, Inc. (ASX:EBR), the medical device company developing wireless cardiac pacing systems, is proud to announce that positive results from the first completely leadless cardiac resynchronization therapy …
COVID-19 Vaccine Protects Against the Corona Virus in Patients with Celiac Disease
A retrospective study undertaken by Maccabi KSM Research in Israel has revealed that the Pfizer COVID-19 vaccine …
First patient treated in the second dose group in Annexin’s RVO study
Annexin Pharmaceuticals announces that all patients in the first dose group with the lowest dose …
The Inner Circle Acknowledges, , Lawrence J. Singerman as a Most Trusted Healthcare Professional for his contributions to the Field of Ophthalmology
The Inner Circle Acknowledges, , Lawrence J. Singerman as a Most Trusted Healthcare Professional for …
Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA …
